INOVIQ Ltd (ASX: IIQ) (INOVIQ) is at the forefront of developing and commercializing next-generation exosome isolation tools and precision diagnostics. Their innovative approach aims to revolutionize the diagnosis and treatment of cancer and other diseases. The company has successfully commercialized the EXO-NET pan-exosome capture tool for research purposes, allowing scientists to efficiently isolate exosomes for further study. Additionally, INOVIQ has introduced the hTERT test as an adjunct to urine cytology testing for bladder cancer, providing clinicians with a more accurate and reliable diagnostic tool. Through their cutting-edge technology and commitment to advancing healthcare, INOVIQ is poised to make a significant impact in the field of precision medicine.